BIOMEDICAL RESEARCH INSIGHTS

洞察前沿,连接科研新知

聚焦合成生物学、AI 靶点发现、临床队列与公共数据库,汇集最新论文摘要与原始出处
每 12 小时采集更新,经人工审核后发布。

前沿研究专业聚合持续更新
PAPER EXPLORER

发现热点论文

每 5 分钟更新缓存
全部共 27 篇
临床队列临床研究Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Treatment patterns and healthcare utilization for patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the Veterans Health Administration (MCLOVA) who were prescribed their first Bruton Tyrosine Kinase inhibitor (BTKi): A national retrospective cohort study.

暂无引用数据

一项基于美国退伍军人健康管理局(VHA)全国数据的回顾性队列研究,纳入2020年1月1日至2023年12月31日期间首次接受布鲁顿酪氨酸激酶抑制剂(BTKi)治疗的复发/难治性套细胞淋巴瘤(R/R MCL)成人患者494例,其中伊布替尼组177例、阿可替尼组189例、泽布替尼组128例。结果显示,伊布替尼组换用其他BTKi的患者比例(27%)高于阿可替尼组(10%,p<0.01)和泽布替尼组(9%,p<0.01);12个月时实验室检查就诊中位数(IQR)伊布替尼组为5(0-12),高于阿可替尼组1(0-8,p<0.01)和泽布替尼组0(0-6,p<0.01)。泽布替尼组总生存期优于伊布替尼组(p<0.01)和阿可替尼组(p<0.01)。结论认为,接受阿可替尼和泽布替尼治疗的患者12个月内实验室及血液/肿瘤科就诊次数少于伊布替尼组,泽布替尼组较伊布替尼组显示出生存优势。

为什么值得关注

暂未整理

查看扩展信息

完整作者

暂未整理

作者机构

暂未整理

技术路线

暂未整理

最近 5 个完整年度引用趋势

暂无引用数据

数据来源:暂未标注更新时间:暂无更新时间
公共数据库临床研究Science progress

Multisystem assessment of the association between physical activity and biological aging: Evidence from a national cross-sectional survey.

暂无引用数据

一项基于美国国家健康与营养调查(NHANES)2003—2010年及2015—2018年数据的横断面研究,纳入13379名中老年人,按自报每周身体活动量(MET-min/周)分为低(<600)、中(600—3000)、高(>3000)三级,综合适应负荷、稳态失调、表型年龄加速和Klemera-Doubal法生物学年龄加速四项指标评估身体活动与多维生物学衰老的关联。加权多变量线性回归显示,调整协变量后,中等水平身体活动与较低的适应负荷(β=-0.219)、表型年龄加速(β=-0.524)和KDM年龄加速(β=-0.638)独立相关;高水平身体活动在各模型中均无显著关联。剂量反应曲线呈非线性,中等水平估计值最有利。亚组分析显示,高水平身体活动在各年龄组与KDM年龄加速呈一致正相关,在癌症幸存者中与稳态失调呈反向关联。结论认为,相对于低水平活动,中等水平身体活动与更有利的生物学衰老指标相关,但关联因维度和亚组而异,未来需开展纵向及干预研究。

为什么值得关注

暂未整理

查看扩展信息

完整作者

暂未整理

作者机构

暂未整理

技术路线

暂未整理

最近 5 个完整年度引用趋势

暂无引用数据

数据来源:暂未标注更新时间:暂无更新时间
公共数据库临床研究Journal of visualized experiments : JoVE

Associations of International Normalized Ratio and Hematocrit With Stroke Status and Machine Learning Mortality Prediction in Critical Care Databases.

暂无引用数据

卒中可致死亡和长期残疾。该回顾性队列研究基于MIMIC-IV和eICU-CRD数据库,纳入29 831例成人ICU患者,依据ICD-9/10编码判定卒中状态,采用入ICU后24 h内首次INR和Hct检测值,通过多因素logistic回归、四分位分析、限制性立方样条、亚组及敏感性分析评估二者与卒中的关联。结果显示,随INR四分位升高卒中比例下降,随Hct四分位升高卒中比例上升;充分校正后,INR每增加1单位卒中风险降低(OR 0.105~0.395),Hct每增加1个百分点卒中风险升高(OR 1.076~1.103);多重插补结果方向一致。卒中患者的事后探索性分析采用Cox回归筛选6个预后变量构建机器学习模型,梯度提升机模型在训练集、内部验证集和外部验证集的AUC分别为0.717、0.670和0.630。结论提示INR与卒中呈负相关、Hct与卒中呈正相关,上述观察性关联需谨慎解读,死亡预测分析为卒中患者提供了补充性预后视角。

为什么值得关注

暂未整理

查看扩展信息

完整作者

Juan Han、Linming Zhang、Chunyan Lei

作者机构

  • Department of Neurology, Hospital of Kunming Medical University; hanjuan@ydyy.cn.
  • Department of Neurology, Hospital of Kunming Medical University.

技术路线

暂未整理

最近 5 个完整年度引用趋势

暂无引用数据

数据来源:暂未标注更新时间:暂无更新时间
临床队列临床研究Nature medicine

Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial.

0 次引用趋势数据不足

2期MDT-BRIDGE研究评估围手术期度伐利尤单抗联合新辅助化疗(AEGEAN方案)用于可切除及临界可切除非小细胞肺癌,并对新辅助化免疫治疗后经多学科团队评估转为不可切除者予以放化疗后度伐利尤单抗巩固(PACIFIC方案)。主要终点为总切除率(描述性,未作正式假设检验);次要终点包括无事件生存期、无进展生存期、可切除队列病理完全缓解率、基线至术前/放化疗前循环肿瘤DNA清除率及安全性。共142例接受新辅助治疗,基线可切除和临界可切除分别占64.8%和35.2%。总切除率(95%CI)为74.6%(66.7‒81.6),手术者R0切除率96.2%(90.6‒99.0)。131例(92.3%)在新辅助治疗后接受手术(106例)或放化疗(25例),117例(82.4%)接受辅助(94例)或巩固(23例)度伐利尤单抗。辅助或巩固度伐利尤单抗期间,手术患者和放化疗患者3/4级不良事件最高发生率分别为7.4%和17.4%,因不良事件停药分别为8.5%和13.0%。该多学科团队指导策略可行,使多数患者接受根治性治疗(手术或放化疗)后予以度伐利尤单抗,并显示初步疗效积极、安全性可控。

为什么值得关注

暂未整理

查看扩展信息

完整作者

Martin Reck、Ernest Nadal、Carl M Gay、Nicolas Girard、Andrea Riccardo Filippi、Linda W Martin、Cordula Petersen、David A Cairns、Margarita Majem、Andrea Ardizzoni、Rosa Alvarez Alvarez、Andrew Robinson、Benoit Roch、Arnaud Boyer、Ilaria Attili、Maximilian Diehn、David Kurtz、Ugochinyere A Emeribe、Ignacio Diaz Perez、Matteo Giaj Levra、Davina Gale、Zhou Zhu、Nefeli Georgoulia、Jonathan Spicer

作者机构

  • Lung Clinic Großhansdorf, Airway Research Center North, German Center for Lung Research, Großhansdorf, Germany. m.reck@lungenclinic.de.
  • Department of Medical Oncology, Institut Català d'Oncologia (ICO), IDIBELL, Bellvitge Healthcare Campus, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Institut du Thorax Curie-Montsouris, Institut Curie/UVSQ, Paris, France.
  • Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Department of Oncology, University of Milan, Milan, Italy.
  • Division of Thoracic Surgery, Department of Surgery, University of Virginia, Charlottesville, VA, USA.
  • Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Department of Medical Oncology, Institut de Recerca Sant Pau (IR Sant Pau), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain.
  • Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, ON, Canada.
  • Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
  • Hôpital Saint Joseph, Marseille, France.
  • Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Department of Radiation Oncology, Stanford University, Stanford, CA, USA.
  • Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
  • AstraZeneca, Wilmington, DE, USA.
  • AstraZeneca, Gaithersburg, MD, USA.
  • AstraZeneca, Cambridge, UK.
  • Department of Thoracic Surgery, McGill University, Montreal, QC, Canada.

技术路线

数据/样本:142例可切除或临界可切除NSCLC患者接受新辅助治疗(64.8%可切除,35.2%临界可切除) → 分析:描述性主要终点总体切除率(74.6%,95%CI 66.7-81.6),R0切除率96.2%(90.6-99.0),并报告无事件生存、无进展生存、病理完全缓解率、循环肿瘤DNA清除及安全性

最近 5 个完整年度引用趋势

0110202102022020230202402025

不含 2026 年,仅展示最近 5 个完整年度。

数据来源:openalex更新时间:2026/10/29 12:33
临床队列临床研究Lancet (London, England)

Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials.

0 次引用趋势数据不足

Remibrutinib是一种高选择性、强效、共价、可穿透中枢神经系统的口服BTK抑制剂。REMODEL-1和REMODEL-2为两项相同的随机、双盲、双模拟、活性对照、平行组、事件驱动Ⅲ期试验,在46个国家407个中心开展,纳入18-55岁、EDSS评分0-5.5、有近期疾病活动证据的复发型多发性硬化患者,按1:1随机接受口服remibrutinib 100 mg每日两次或特立氟胺14 mg每日一次,主要终点为年化复发率(ARR)。2021年12月13日至2025年12月30日筛查2632例,随机分配2007例;REMODEL-1纳入1000例,REMODEL-2纳入1007例。remibrutinib组ARR显著低于特立氟胺组:REMODEL-1为0.073 vs 0.112(RR 0.648,95%CI 0.453-0.927;p=0.018),REMODEL-2为0.080 vs 0.116(RR 0.688,95%CI 0.487-0.972;p=0.034)。最常见不良事件为上呼吸道感染、鼻咽炎、腹泻和脱发;导致停药的不良事件remibrutinib组较少(3.1% vs 5.8%),安全性与其他适应症一致,无肝脏安全性担忧。研究表明remibrutinib优于特立氟胺且安全性良好,支持其作为复发型多发性硬化潜在新型口服治疗选择。

为什么值得关注

暂未整理

查看扩展信息

完整作者

Heinz Wiendl、Robert Bermel、Laura Airas、Tanuja Chitnis、Jin Nakahara、Mitzi Williams、Monika Adamczyk-Sowa、Karolina Piasecka-Stryczynska、Ronald Zielman、Sinead Dunphy、Nicolas Panchaud、Min Cai、Jing Xi、Brett Loop、Wendy Su、Roman Willi、Xavier Montalban、REMODEL Investigators

作者机构

  • Department of Neurology and Neurophysiology, University of Freiburg, Freiburg, Germany; Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia. Electronic address: heinz.wiendl@uniklinik-freiburg.de.
  • Department of Neurology, Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA.
  • Turku PET Centre, Clinical Neurosciences and InFLAMES Research Flagship, University of Turku, Turku, Finland; Neurocenter, Turku University Hospital, Turku, Finland.
  • Brigham Multiple Sclerosis Center and Division of Neuroimmunology, Mass General Brigham, Boston, MA, USA.
  • Department of Neurology, Keio University School of Medicine, Tokyo, Japan.
  • Joi Life Wellness Neurology Clinic, Smyrna, GA, USA.
  • Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
  • MedPolonia, Outpatient MS Clinic, Poznań, Poland; Department of Medical Education and Communication, Poznan University of Medical Sciences, Poznań, Poland.
  • Novartis Pharma, Basel, Switzerland.
  • Novartis Ireland, Dublin, Ireland.
  • Novartis Institutes for Biomedical Research, Shanghai, China.
  • Novartis Pharmaceuticals Corporation, Cambridge, MA, USA.
  • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat de Vic-Universitat Central de Catalunya (UVic-UCC), Barcelona, Spain.

技术路线

数据/样本:REMODEL-1和REMODEL-2两项相同的随机、双盲、双模拟、活性对照、平行组、事件驱动3期试验,46国407中心,共随机2007例复发型多发性硬化成人患者(REMODEL-1 1000例,REMODEL-2 1007例)。分析:主要终点为年化复发率(ARR),在意向治疗(所有随机分配)人群中评估,比较remibrutinib 100 mg每日两次与特立氟胺14 mg每日一次,并报告安全性。验证:原文未报告独立验证或额外确认性分析。

最近 5 个完整年度引用趋势

0110202102022020230202402025

不含 2026 年,仅展示最近 5 个完整年度。

数据来源:openalex更新时间:2026/10/29 12:34
公共数据库研究类型未标注Nature genetics

Genome-wide detection of genotype-environment interactions at biobank scale with fastGxE.

0 次引用趋势数据不足

传统全基因组关联研究多关注基因主效应,常忽略基因-环境交互作用(GxE)。为此,研究者提出可扩展且有效的全基因组GxE分析方法fastGxE,用于识别与环境因素交互影响目标性状的遗传变异。该方法可控制多基因效应、多基因交互效应及噪声异质性,对参与交互的环境因素数量保持稳健,并确保大型生物样本库全基因组GxE分析的可扩展性,速度较现有方法提升32.98–126.49倍。通过广泛模拟及对英国生物样本库32项身体性状和67项血液生物标志物的深入分析,fastGxE在身体性状中识别出7个相关基因组位点(含4个新位点),在血液生物标志物中识别出18个相关位点(其中12个为新位点)。

为什么值得关注

暂未整理

查看扩展信息

完整作者

Chao Ning、Xiang Zhou

作者机构

  • Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
  • Department of Statistics and Data Science, Yale University, New Haven, CT, USA. xiang.zhou.xz735@yale.edu.

技术路线

数据/样本:UK Biobank的32项体格性状和67项血液生物标志物数据,辅以广泛模拟数据;分析:全基因组基因-环境交互分析(fastGxE),控制多基因效应、多基因交互效应和噪声异质性;无独立验证步骤报告

最近 5 个完整年度引用趋势

0110202102022020230202402025

不含 2026 年,仅展示最近 5 个完整年度。

数据来源:openalex更新时间:2026/10/29 12:35
公共数据库综述Nature genetics

Genome-wide analyses identify 60 loci associated with liver triglyceride content.

0 次引用趋势数据不足

研究对来自英国生物银行的71,488名欧洲血统参与者的磁共振成像衍生肝脏甘油三酯含量进行了大规模全基因组关联研究荟萃分析,样本量约为既往研究的2倍。共识别60个独立位点,其中31个为新发现;肝脏甘油三酯含量的单核苷酸多态性遗传率估计为25%。整合精细定位与基因优先排序分析为48个位点提名了候选效应基因。31个新发现变异中有14个在临床诊断的代谢功能障碍相关脂肪性肝病荟萃分析(42,163例病例和1,646,254例对照)中得到验证。肝脏甘油三酯含量多基因风险评分最高十分位者较最低十分位者肝硬化风险高2.71倍,肝细胞癌风险高7.47倍。与多基因风险评分相关的血浆蛋白富集于代谢重塑和炎症通路,遗传风险越高,肝脏富集蛋白特征越强,内脏脂肪特征越弱。研究细化了肝脏甘油三酯含量的遗传结构,将多基因易感性同下游代谢与炎症通路联系起来,为脂肪性肝病的遗传基础提供了见解。

为什么值得关注

暂未整理

查看扩展信息

完整作者

Oveis Jamialahmadi、Shahir Mowlaei、Kyla Z Gelev、Rosellina M Mancina、Valentina Flagiello、Julia Kozlitina、Päivi Pajukanta、Luca Valenti、Stefano Romeo

作者机构

  • Centre for Reproduction, Metabolism and Molecular Medicine (CeRM), Department of Medicine, Karolinska Institute, Huddinge, Sweden. oveis.jamialahmadi@ki.se.
  • Centre for Reproduction, Metabolism and Molecular Medicine (CeRM), Department of Medicine, Karolinska Institute, Huddinge, Sweden.
  • Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Department of Life Science, Health, and Health Professions, Link Campus University, Rome, Italy.
  • Operative Research Unit of Clinical Medicine and Hepatology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  • The Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Bioinformatics Interdepartmental Program, UCLA, Los Angeles, CA, USA.
  • Institute for Precision Health, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
  • Precision Medicine and Biological Resource Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy.
  • Centre for Reproduction, Metabolism and Molecular Medicine (CeRM), Department of Medicine, Karolinska Institute, Huddinge, Sweden. stefano.romeo@ki.se.
  • Department of Endocrinology, Karolinska University Hospital, Huddinge, Sweden. stefano.romeo@ki.se.
  • Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy. stefano.romeo@ki.se.
  • Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden. stefano.romeo@ki.se.
  • Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden. stefano.romeo@ki.se.

技术路线

MRI衍生肝脏甘油三酯含量数据(71,488名欧洲 ancestry UK Biobank参与者)→全基因组关联研究荟萃分析→识别60个独立位点(31个新位点)并估计SNP遗传力为25%→整合精细定位与基因优先级分析提名48个位点的候选效应基因→在临床诊断的代谢功能障碍相关脂肪性肝病荟萃分析(42,163例病例和1,646,254例对照)中验证31个新位点中的14个→多基因风险评分与肝硬化(OR 2.71)和肝细胞癌(OR 7.47)风险关联分析→与多基因风险评分相关的血浆蛋白通路富集分析(代谢重塑和炎症通路,肝脏富集蛋白特征增加、内脏脂肪特征减少)

最近 5 个完整年度引用趋势

0110202102022020230202402025

不含 2026 年,仅展示最近 5 个完整年度。

数据来源:openalex更新时间:2026/10/29 12:36
临床队列临床研究Nature

Divergent genomic evolution in astrocytomas and oligodendrogliomas.

0 次引用趋势数据不足

一项发表于《自然》的研究利用全基因组和全外显子组测序,对胶质瘤纵向分析联盟收集的183例IDH突变型胶质瘤患者的纵向肿瘤标本进行了分析,多数原发手术样本组织学分级为2级(星形细胞瘤73%,少突胶质细胞瘤93%)。研究验证了肿瘤进展的已知基因组标志物,包括超突变及CDKN2A/B纯合缺失,并发现星形细胞瘤与少突胶质细胞瘤的演化轨迹存在差异:复发性少突胶质细胞瘤新获得PI3K和NOTCH1突变,与肿瘤突变负荷增加相关;复发性星形细胞瘤则获得局灶性癌基因扩增和CDKN2A/B纯合缺失,与染色体失衡增加相关,并伴随染色体碎裂和全基因组加倍等标志。两类肿瘤均出现获得性改变与全基因组变化的趋同及患者预后恶化,提示治疗难治性克隆被选择。替莫唑胺治疗与SBS11和SBS119突变特征相关,放疗相关ID8特征仅在星形细胞瘤中增加。研究表明,两类肿瘤基因组以不同方式适应肿瘤进展和治疗的选择压力。

为什么值得关注

编辑短评

该研究基于183例IDH突变胶质瘤纵向标本,通过全基因组/外显子测序揭示星形细胞瘤与少突胶质细胞瘤在进展和治疗压力下的基因组演化差异,并验证已知进展标志物。样本量较大、纵向设计及治疗相关突变特征分析增强了发现的可信度。但摘要未报告具体效应量、统计显著性及独立验证队列,结论的普适性仍需进一步确认。

查看扩展信息

完整作者

Tamrin Chowdhury、C Mircea S Tesileanu、Emre Kocakavuk、Kevin C Johnson、Joo Ho Lee、Zeynep Erson-Omay、Chaewon Heo、Kenneth Aldape、Samirkumar B Amin、Kevin J Anderson、David M Ashley、Floris P Barthel、Jill S Barnholtz-Sloan、Daniel J Brat、Andrew R Brodbelt、Ana Valeria Castro、Elizabeth B Claus、Jennifer M Connelly、Joseph F Costello、Indrani Datta、Carol Elliott、Gaetano Finocchiaro、Pim J French、Hui K Gan、Luciano Garofano、Padmaja L Ghospurkar、Anna Golebiewska、Pranav S Gundla、Beth Hermes、Chibo Hong、Youri Hoogstrate、Craig Horbinski、Jason T Huse、Antonio Iavarone、Cihat Karadag、Mustafa Khasraw、Mathilde C M Kouwenhoven、Peter S LaViolette、Kay Li、Allison Lowman、Katy McCortney、Hyo-Eun Moon、Nader Sanai、MacLean P Nasrallah、H K Ng、D Ryan Ormond、Bethany Kwan、Marta Padovan、Sun Ha Paek、Laila M Poisson、Sushant Puri、Erica Shen、Shwetal Mehta、Andrew E Sloan、Wies R Vallentgoed、Erwin G Van Meir、Rachael Vaubel、Taylor E Wade、Annemiek M E Walenkamp、Colin Watts、Tobias Weiss、Michael Weller、Pieter Wesseling、Kerryn Westcott、Bart A Westerman、Gordon Y Ye、W K Alfred Yung、GLASS Consortium、Frederick S Varn、Roel G W Verhaak

作者机构

  • Department of Neurosurgery, Yale University, New Haven, CT, USA.
  • Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), National Center for Tumor Diseases (NCT) West, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Department of Radiation Oncology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea.
  • Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
  • National Institutes of Health, Bethesda, MD, USA.
  • The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
  • Preston Robert Tisch Brain Tumor Center at Duke University, Durham, NC, USA.
  • Translational Genomics Research Institute, Phoenix, AZ, USA.
  • National Cancer Institute, Bethesda, MD, USA.
  • Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Walton Centre NHS Foundation Trust, Liverpool, UK.
  • Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Health, Detroit, MI, USA.
  • Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.
  • Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
  • Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Department of Neurosurgery, University of California, San Francisco, San Francisco, CA, USA.
  • St Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
  • Department of Neurology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Department of Neurology, Erasmus University Medical Centre Rotterdam, Rotterdam, The Netherlands.
  • Cancer Therapies and Biology Laboratory, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia.
  • Department of Public Health Sciences, Division of Biostatistics and Bioinformatics, Miller School of Medicine, University of Miami, Miami, FL, USA.
  • Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA.
  • NORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
  • Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Neurological Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.
  • Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.
  • Department of Neurology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Department of Radiology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Department of Pathology, Prince of Wales Hospital, Hong Kong, China.
  • Department of Neurosurgery, Cancer Research Institute, Hypoxia/Ischemia Disease Institute, Seoul National University, Seoul, Republic of Korea.
  • Ivy Brain Tumor Center at the Barrow Neurological Institute, Phoenix, AZ, USA.
  • Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Neurosurgery, University of Colorado Anschutz School of Medicine, Aurora, CO, USA.
  • Department of Emergency Medicine, University of Colorado Anschutz School of Medicine, Aurora, CO, USA.
  • Advanced Institutes of Convergence Technology, Seoul National University, Suwon-si, Republic of Korea.
  • Oregon Health & Science University, Portland, OR, USA.
  • Neurological Institute, Premier Health and Wright State University School of Medicine, Dayton, OH, USA.
  • University of Alabama at Birmingham (UAB), Birmingham, AL, USA.
  • Division of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA.
  • Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Department of Cancer Genome Sciences, University of Birmingham, Birmingham, UK.
  • Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
  • VUmc, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Department of Neurosurgery, VUmc, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • University of California, San Diego, La Jolla, CA, USA.
  • Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA. frederick.varn@jax.org.
  • Department of Genetics and Genome Sciences, University of Connecticut Health Center, Farmington, CT, USA. frederick.varn@jax.org.
  • Institute for Systems Genomics, University of Connecticut, Storrs, CT, USA. frederick.varn@jax.org.
  • Department of Neurosurgery, Yale University, New Haven, CT, USA. roel.verhaak@yale.edu.

技术路线

['数据/样本:183例IDH突变型胶质瘤患者的纵向收集肿瘤标本(来自GLASS联盟)', '分析:全基因组测序和全外显子组测序,表征纵向标本的遗传驱动因素;验证已知进展基因组标志物(超突变、CDKN2A/B纯合缺失),发现区分星形细胞瘤与少突胶质细胞瘤演化轨迹的遗传改变;分析获得性改变、全基因组变化与患者结局的趋同;关联治疗(替莫唑胺、放疗)与突变特征', '验证:验证已知基因组标志物(超突变和CDKN2A/B纯合缺失)']

最近 5 个完整年度引用趋势

0110202102022020230202402025

不含 2026 年,仅展示最近 5 个完整年度。

数据来源:openalex更新时间:2026/10/30 06:02
临床队列临床研究Nature medicine

Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.

0 次引用趋势数据不足

一项1期临床试验评估了个性化新抗原靶向癌症疫苗用于高级别上皮性卵巢癌的可行性与安全性。该疫苗“NeoVax”由靶向患者特异性新抗原的合成长肽池与免疫刺激剂poly-ICLC混合而成,联合延迟给予抗PD-1抗体,在10例铂敏感卵巢癌患者中测试(1例新诊断者为A队列,9例首次复发者为B队列),均在标准铂类双药化疗后接种。可评估的B队列12例中9例接种(75%,90%CI 47-93%),A队列9例中1例接种(11%,90%CI 0.6-43%)。未出现意外安全信号,无患者因毒性停止治疗。尽管从诊断活检到疫苗接种中位间隔6.5个月且期间接受标准化疗,>70%的选定靶点仍可通过无创游离DNA分析检测到。生物标志物分析提示10例中6例存在疫苗生物学活性,且与接种后血液和肿瘤中更广泛的肿瘤及疫苗特异性免疫应答相关。耐药肿瘤克隆反映影响抗原呈递的多种机制,提示疫苗接种施加了免疫选择压力。总体而言,肿瘤呈递抗原谱与诱导免疫广度之间的相互作用似乎决定接种后的临床疗效。ClinicalTrials.gov注册号:NCT04024878。

为什么值得关注

暂未整理

查看扩展信息

完整作者

MacLean C Sellars、Jessica A Frank、Bohoon Shim、Allison Vanasse、Ruolin Liu、Cleo Forman、Chloe R Tu、Kyohei K Tabata、Antonia Kowelewski、Su-Chun Cheng、Catherine Song、Kan Xiong、Pia Jain、Andjela Crnjac、Haley E Sax、Vipheaviny Chea、Wesley Lu、J Thomas Janes、Micah Rickles-Young、Amit Sud、Savni Sarolkar、Martin Hayes、Oriol Olive、Haley Greenslade、Carrie Cibulskis、Nir Hacohen、Edward F Fritsch、Shuqiang Li、Kenneth J Livak、Nabihah Tayob、Elizabeth H Stover、Carolyn Krasner、Rebecca Porter、Ursula Matulonis、Gad Getz、Giacomo Oliveira、Patrick A Ott、Jeremy M Simon、Viktor A Adalsteinsson、Derin B Keskin、Panagiotis A Konstantinopoulos、Catherine J Wu

作者机构

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Harvard Medical School, Boston, MA, USA.
  • Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Centre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
  • Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
  • Department of Pathology, Harvard Medical School, Boston, MA, USA.
  • Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
  • Department of Medical Education and Biomedical Sciences, Methodist University CFVH School of Medicine, Fayetteville, NC, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Panogiotis_Konstantinopoulos@dfci.harvard.edu.
  • Harvard Medical School, Boston, MA, USA. Panogiotis_Konstantinopoulos@dfci.harvard.edu.
  • Mellen and Eisenson Family Center for BRCA and Related Genes, Dana-Farber Cancer Institute, Boston, MA, USA. Panogiotis_Konstantinopoulos@dfci.harvard.edu.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Catherine_Wu@dfci.harvard.edu.
  • Harvard Medical School, Boston, MA, USA. Catherine_Wu@dfci.harvard.edu.
  • Broad Institute of MIT and Harvard, Cambridge, MA, USA. Catherine_Wu@dfci.harvard.edu.
  • Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. Catherine_Wu@dfci.harvard.edu.

技术路线

肿瘤样本/诊断活检 → 个体化新抗原筛选与合成多肽库(NeoVax)制备

最近 5 个完整年度引用趋势

0110202102022020230202402025

不含 2026 年,仅展示最近 5 个完整年度。

数据来源:openalex更新时间:2026/10/29 12:35
公共数据库临床研究Frontiers in epidemiology

Red blood cell distribution width and all-cause mortality in low-income populations: a NHANES-based cohort study.

暂无引用数据

基于NHANES 1999—2016数据库,本研究纳入17,412名低收入(家庭收入与贫困线比值<1)成人,随访至2016年12月31日,采用加权多变量Cox回归分析红细胞分布宽度(RDW)与全因死亡的关系。结果发现,RDW与全因死亡呈非线性关联,阈值為15.9%;低于该阈值时,RDW每升高1%,死亡风险增加29%(HR=1.29,95%CI:1.20~1.38,P<0.0001),高于阈值后关联无统计学意义。多变量校正后,RDW每升高1%,全因死亡风险增加11%(HR=1.11,95%CI:1.08~1.15,P<0.0001)。研究表明,低收入成人中RDW升高与全因死亡风险增加相关,可能作为该人群死亡风险的预后标志物,其临床预测价值尚需进一步研究验证。

为什么值得关注

暂未整理

查看扩展信息

完整作者

暂未整理

作者机构

暂未整理

技术路线

暂未整理

最近 5 个完整年度引用趋势

暂无引用数据

数据来源:暂未标注更新时间:暂无更新时间
页